Preclinical Evaluation of Adjuvant Therapy with AMD3100 for Drug Resistant Philadelphia Chromosome Positive and Negative ALL
Jiang E, Yu M, Hsieh Y, DeLaTorre B, Kadavallore A, Scharman C, Park E, Yang A, Muschen M, Groffen J, Heisterkamp N, Kim Y. Preclinical Evaluation of Adjuvant Therapy with AMD3100 for Drug Resistant Philadelphia Chromosome Positive and Negative ALL. Blood 2008, 112: 2922. DOI: 10.1182/blood.v112.11.2922.2922.Peer-Reviewed Original ResearchAcute lymphoblastic leukemiaNOD/SCIDDrug-resistant leukemia cellsResistant leukemia cellsLeukemia cellsPreclinical evaluationPre-clinical xenograft modelNOD/SCID miceAcute lymphoblastic leukemia cellsCombination of AMD3100Different chemotherapeutic regimensNew treatment modalitiesLong-term survivalPrimary lymphoid organsLymphoblastic leukemia cellsTail vein injectionFurther preclinical evaluationCXCL12-CXCR4 interactionProgression of leukemiaB cell precursorsHigh death rateInteraction of CXCL12Clear beneficial effectPhiladelphia Chromosome PositiveBone marrow fibroblasts